Cargando…
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis
BACKGROUND: Serum chitotriosidase is a promising biomarker that has shown high specificity and sensitivity in patients with sarcoidosis. The aim of this study was to investigate correlations between serum chitotriosidase, clinical phenotypes, disease localizations and different radiological lung inv...
Autores principales: | Bennett, David, Cameli, Paolo, Lanzarone, Nicola, Carobene, Loredana, Bianchi, Nicola, Fui, Annalisa, Rizzi, Luigi, Bergantini, Laura, Cillis, Giuseppe, Miriana, D’ Alessandro, Mazzei, Maria Antonietta, Refini, Rosa Metella, Sestini, Piersante, Bargagli, Elena, Rottoli, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945638/ https://www.ncbi.nlm.nih.gov/pubmed/31906975 http://dx.doi.org/10.1186/s12931-019-1263-z |
Ejemplares similares
-
Correction to: Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis
por: Bennett, David, et al.
Publicado: (2020) -
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6
por: Bergantini, Laura, et al.
Publicado: (2019) -
Adaptive immune system in pulmonary sarcoidosis—Comparison of peripheral and alveolar biomarkers
por: d’Alessandro, Miriana, et al.
Publicado: (2021) -
The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis
por: Refini, Rosa Metella, et al.
Publicado: (2020) -
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
por: Cameli, Paolo, et al.
Publicado: (2020)